Failure mode and effects analysis in pharmaceutical research

International Journal of Quality and Service Sciences

Volumn 2, Issue 3, 2010, Pages 369-382

  Inoue, Hirotaka ^a   Yamada, Shu ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Failure mode and effects analysis; Pharmaceuticals industry; Research

Indexed keywords

EID: 84986135999     PISSN: 1756669X     EISSN: 17566703     Source Type: Journal    
DOI: 10.1108/17566691011090080     Document Type: Article

References (24)

1. Adachi, W.I. and Lodolce, A.E. (2005), “Use of failure mode and effects analysis in improving the safety of i.v. drug administration”, American Journal of Health-system Pharmacy, Vol. 62, pp. 917-20.
2. Cai, W., Rao, J., Gambhir, S.S. and Chen, X. (2006), “How molecular imaging is speeding up antiangiogenic drug development”, Molecular Cancer Therapeutics, Vol. 5 No. 11, pp. 2624-33.
3. Cecelia, M. (2006), “Using a FMEA in a service setting”, Quality Progress, Vol. 39 No. 9, pp. 24-9.
4. DeRosier, J., Stalhandske, E., Bagian, J.P. and Nudell, T. (2002), “Using health care failure mode and effects analysis: the VA national center for patient safety's prospective risk analysis system”, The Joint Commission Journal on Quality Improvement, Vol. 28 No. 5, pp. 248-67.
5. Gelijns, A.C., Rosenbert, N. and Moskowitz, A.J. (1998), “Capturing the unexpected benefits of medical research”, New England Journal of Medicine, Vol. 399, pp. 693-8.
6. Krouwer, J.S. (2004), “An improved failure mode effects analysis for hospitals”, Archives of Pathology and Laboratory Medicine, Vol. 128 No. 6, pp. 663-4.
7. Kwak, Y.H. and Anbarib, F.T. (2006), “Benefits, obstacles, and future of six sigma approach”, Technovation, Vol. 26 Nos 5-6, pp. 708-15.
8. Nettekoven, M. and Thomas, A.W. (2002), “Accelerating drug discovery by integrative implementation of laboratory automation in the work flow”, Current Medicinal Chemistry, Vol. 9 No. 23, pp. 2179-90.
9. Nielsch, U., Schäfer, S., Wild, H. and Busch, A. (2007), “One target-multiple indications: a call for an integrated common mechanisms strategy”, Drug Discovery Today, Vol. 12 Nos 23/24, pp. 1025-31.
10. Project Management Institute (2000), A Guide to the Project Management Body of Knowledge (PMBOK® Guide), Project Management Institute, Newtown Square, PA.
11. Reader, J.C. (2004), “Automation in medicinal chemistry”, Current Topics in Medicinal Chemistry, Vol. 4 No. 7, pp. 671-86.
12. Reeves, C.A. and Bednar, D.A. (1993), “What prevents TQM implementation in health care organizations?”, Quality Progress, Vol. 26 No. 4, pp. 41-4.
13. Rhee, S.J. and Ishii, K. (2003), “Using cost based FMEA to enhance reliability and serviceability”, Advanced Engineering Informatics, Vol. 17 Nos 3/4, pp. 179-88.
14. Scipioni, A., Saccarola, G., Centazzao, A. and Arena, F. (2002), “FMEA methodology design, implementation and integration with HACCP system in a food company”, Food Control, Vol. 13, pp. 495-501.
15. Sewing, A., Winchester, T., Carnell, P., Hampton, D. and Keighley, W. (2008), “Helping science to succeed: improving processes in R&D”, Drug Discovery Today, Vol. 13 Nos 5-6, pp. 227-33.
16. Tanaka, K. (2002), “FMEA: an effective method for preventing troubles”, Journal of National Institute of Public Health, Vol. 51 No. 3, pp. 150-3.
17. Tartaglia, L.A. (2006), “Complementary new approaches enable repositioning of failed drug candidates”, Expert Opinion on Investigational Drugs, Vol. 15 No. 11, pp. 1295-8.
18. Teng, S.H. and Ho, S.Y. (1996), “Failure mode and effects analysis: an integrated approach for product design and process control”, International Journal of Quality & Reliability Management, Vol. 13 No. 5, pp. 8-26.
19. Thomas, A.C. and Donald, D.T. (2004), “Project risk management using the project risk FMEA”, Engineering Management Journal, Vol. 16 No. 4, pp. 28-35.
20. van der Greef, J. and McBurney, R.N. (2005a), “Innovation: rescuing drug discovery: in vivo systems pathology and systems pharmacology”, Nature Reviews Drug Discovery, Vol. 4 No. 12, pp. 961-7.
21. van der Greef, J. and McBurney, R.N. (2005b), “Rescuing drug discovery: in vivo systems pathology and systems pharmacology”, Nature Reviews Drug Discovery, Vol. 4 No. 11, pp. 961-7.
22. Handen, J.S. (2002), “The industrialization of drug discovery”, Drug Discovery Today, Vol. 7 No. 2, pp. 83-5.
23. Showalter, H.D.D. and Denny, W.A. (2008), “A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment”, Tuberculosis, Vol. 88 No. 1, pp. S3-17.
24. Veterans Health Administration National Center for Patient Safety (2005), “Healthcare failure mode and effects analysis course materials (HFMEA)”, available at: www.patientsafety.gov/HFMEA.html.